Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Major Depressive Disorder
NCT03554174Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- Feb 2018
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in major depressive disorder (MDD) (4 arms), sponsored by Yale University. Primary endpoint: Electroencephalography at 2 weeks. Started Feb 2018; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03554174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554174.